start-ver=1.4
cd-journal=joma
no-vol=124
cd-vols=
no-issue=3
article-no=
start-page=243
end-page=247
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2012
dt-pub=20121203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A case of intracystic carcinoma of the breast showing pathological complete response by neoadjuvant chemotherapy
kn-title=術前化学療法により壁が菲薄化し組織学的寛解(pCR)となった巨大嚢胞内乳癌の1例
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= A 31-year-old woman presented to our hospital because of a lump 5cm in diameter in her right breast. Ultrasonography revealed a multilocular cystic mass with partial thickening of the wall and the septum. Core needle biopsy (CNB) of the septum confirmed invasive ductal carcinoma. The patient was administered neoadjuvant chemotherapy consisting of 12 cycles of weekly paclitaxel followed by 4 cycles of FEC (5FU, Epilubicin and cyclophosphamide). While the thickness of the wall and septum became thinner, the tumor size did not change in diameter. She underwent right mastectomy and sentinel node biopsy. Post-surgical histopathological findings showed a pathological complete response (pCR).
We report a rare case of invasive ductal carcinoma presenting a multilobular phenotype which showed pCR by neoadjuvant chemotherapy despite no size reduction of the tumor.
en-copyright=
kn-copyright=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=今田孝子
kn-aut-sei=今田
kn-aut-mei=孝子
aut-affil-num=1
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=2
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=3
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=岩本高行
kn-aut-sei=岩本
kn-aut-mei=高行
aut-affil-num=4
ORCID=
en-aut-name=OomoriMasako
en-aut-sei=Oomori
en-aut-mei=Masako
kn-aut-name=大森昌子
kn-aut-sei=大森
kn-aut-mei=昌子
aut-affil-num=5
ORCID=
en-aut-name=IhaSigemichi
en-aut-sei=Iha
en-aut-mei=Sigemichi
kn-aut-name=伊波茂道
kn-aut-sei=伊波
kn-aut-mei=茂道
aut-affil-num=6
ORCID=
en-aut-name=HongoToshie
en-aut-sei=Hongo
en-aut-mei=Toshie
kn-aut-name=本後登志江
kn-aut-sei=本後
kn-aut-mei=登志江
aut-affil-num=7
ORCID=
en-aut-name=HenmiNoriko
en-aut-sei=Henmi
en-aut-mei=Noriko
kn-aut-name=逸見典子
kn-aut-sei=逸見
kn-aut-mei=典子
aut-affil-num=8
ORCID=
en-aut-name=MakabeMikio
en-aut-sei=Makabe
en-aut-mei=Mikio
kn-aut-name=真壁幹夫
kn-aut-sei=真壁
kn-aut-mei=幹夫
aut-affil-num=9
ORCID=
en-aut-name=NogamiHiromi
en-aut-sei=Nogami
en-aut-mei=Hiromi
kn-aut-name=野上浩實
kn-aut-sei=野上
kn-aut-mei=浩實
aut-affil-num=10
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=5
en-affil=
kn-affil=岡山大学病院 病理診断科
affil-num=6
en-affil=
kn-affil=岡山大福クリニック
affil-num=7
en-affil=
kn-affil=岡山大福クリニック
affil-num=8
en-affil=
kn-affil=岡山大福クリニック
affil-num=9
en-affil=
kn-affil=岡山中央病院
affil-num=10
en-affil=
kn-affil=野上病院
en-keyword=嚢胞内乳癌(intracystic breast cancer)
kn-keyword=嚢胞内乳癌(intracystic breast cancer)
en-keyword=術前化学療法(neoadjuvant chemotherapy)
kn-keyword=術前化学療法(neoadjuvant chemotherapy)
en-keyword=組織学的完全奏功(pahthological CR)
kn-keyword=組織学的完全奏功(pahthological CR)
END
start-ver=1.4
cd-journal=joma
no-vol=124
cd-vols=
no-issue=3
article-no=
start-page=271
end-page=272
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2012
dt-pub=20121203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 17th Congress of the Japanese Society for Palliative Medicine
kn-title=第17回日本緩和医療学会学術大会報告
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=1
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 緩和医療学
END
start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=1
article-no=
start-page=25
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20140401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
kn-title=早期乳癌におけるOne-step Nucleic Acid Amplification(OSNA)法によるセンチネルリンパ節転移診断の検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.
Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.
Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.
Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
en-copyright=
kn-copyright=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=溝尾妙子
kn-aut-sei=溝尾
kn-aut-mei=妙子
aut-affil-num=1
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=枝園忠彦
kn-aut-sei=枝園
kn-aut-mei=忠彦
aut-affil-num=2
ORCID=
en-aut-name=ItoMaiko
en-aut-sei=Ito
en-aut-mei=Maiko
kn-aut-name=伊藤麻衣子
kn-aut-sei=伊藤
kn-aut-mei=麻衣子
aut-affil-num=3
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=野上智弘
kn-aut-sei=野上
kn-aut-mei=智弘
aut-affil-num=4
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=岩本高行
kn-aut-sei=岩本
kn-aut-mei=高行
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=6
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=平成人
kn-aut-sei=平
kn-aut-mei=成人
aut-affil-num=7
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=8
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=土井原博義
kn-aut-sei=土井原
kn-aut-mei=博義
aut-affil-num=9
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=2
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=3
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=4
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=5
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=6
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=7
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=8
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=9
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
en-keyword=OSNA法(OSNA method)
kn-keyword=OSNA法(OSNA method)
en-keyword=センチネルリンパ節(sentinel lymph node)
kn-keyword=センチネルリンパ節(sentinel lymph node)
en-keyword=micrometastases
kn-keyword=micrometastases
en-keyword=CK-19
kn-keyword=CK-19
END
start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=2
article-no=
start-page=133
end-page=135
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20140801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Treatment for a non-compliant patient with cancer and epilepsy
kn-title=癌告知後の精神症状の治療に難渋したてんかん既往のある癌患者の1例
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy.
en-copyright=
kn-copyright=
en-aut-name=MinamiDaisuke
en-aut-sei=Minami
en-aut-mei=Daisuke
kn-aut-name=南大輔
kn-aut-sei=南
kn-aut-mei=大輔
aut-affil-num=1
ORCID=
en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=市原英基
kn-aut-sei=市原
kn-aut-mei=英基
aut-affil-num=2
ORCID=
en-aut-name=OkabeNobuyuki
en-aut-sei=Okabe
en-aut-mei=Nobuyuki
kn-aut-name=岡部伸幸
kn-aut-sei=岡部
kn-aut-mei=伸幸
aut-affil-num=3
ORCID=
en-aut-name=YokomichiNaosuke
en-aut-sei=Yokomichi
en-aut-mei=Naosuke
kn-aut-name=横道直佑
kn-aut-sei=横道
kn-aut-mei=直佑
aut-affil-num=4
ORCID=
en-aut-name=KougeNoriko
en-aut-sei=Kouge
en-aut-mei=Noriko
kn-aut-name=高下典子
kn-aut-sei=高下
kn-aut-mei=典子
aut-affil-num=5
ORCID=
en-aut-name=KajizonoMakoto
en-aut-sei=Kajizono
en-aut-mei=Makoto
kn-aut-name=鍛治園誠
kn-aut-sei=鍛治園
kn-aut-mei=誠
aut-affil-num=6
ORCID=
en-aut-name=AkimotoYutaka
en-aut-sei=Akimoto
en-aut-mei=Yutaka
kn-aut-name=秋元悠
kn-aut-sei=秋元
kn-aut-mei=悠
aut-affil-num=7
ORCID=
en-aut-name=HoriKeisuke
en-aut-sei=Hori
en-aut-mei=Keisuke
kn-aut-name=堀圭介
kn-aut-sei=堀
kn-aut-mei=圭介
aut-affil-num=8
ORCID=
en-aut-name=MatsubaraMinoru
en-aut-sei=Matsubara
en-aut-mei=Minoru
kn-aut-name=松原稔
kn-aut-sei=松原
kn-aut-mei=稔
aut-affil-num=9
ORCID=
en-aut-name=NasuJunichiro
en-aut-sei=Nasu
en-aut-mei=Junichiro
kn-aut-name=那須淳一郎
kn-aut-sei=那須
kn-aut-mei=淳一郎
aut-affil-num=10
ORCID=
en-aut-name=TanimotoMitsune
en-aut-sei=Tanimoto
en-aut-mei=Mitsune
kn-aut-name=谷本光音
kn-aut-sei=谷本
kn-aut-mei=光音
aut-affil-num=11
ORCID=
en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=木浦勝行
kn-aut-sei=木浦
kn-aut-mei=勝行
aut-affil-num=12
ORCID=
en-aut-name=MatsuokaJunzi
en-aut-sei=Matsuoka
en-aut-mei=Junzi
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=13
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学病院 緩和支持医療科
affil-num=2
en-affil=
kn-affil=岡山大学病院 血液・腫瘍・呼吸器内科
affil-num=3
en-affil=
kn-affil=岡山大学病院 精神科神経科
affil-num=4
en-affil=
kn-affil=岡山大学病院 緩和支持医療科
affil-num=5
en-affil=
kn-affil=岡山大学病院 看護部
affil-num=6
en-affil=
kn-affil=岡山大学病院 薬剤部
affil-num=7
en-affil=
kn-affil=岡山大学病院 消化器内科
affil-num=8
en-affil=
kn-affil=岡山大学病院 消化器内科
affil-num=9
en-affil=
kn-affil=岡山大学病院 消化器内科
affil-num=10
en-affil=
kn-affil=岡山大学病院 消化器内科
affil-num=11
en-affil=
kn-affil=岡山大学病院 血液・腫瘍・呼吸器内科
affil-num=12
en-affil=
kn-affil=岡山大学病院 血液・腫瘍・呼吸器内科
affil-num=13
en-affil=
kn-affil=岡山大学病院 緩和支持医療科
en-keyword=てんかん(epilepsy)
kn-keyword=てんかん(epilepsy)
en-keyword=易怒性(irritability)
kn-keyword=易怒性(irritability)
en-keyword=適応障害(maladjustment)
kn-keyword=適応障害(maladjustment)
END
start-ver=1.4
cd-journal=joma
no-vol=143
cd-vols=
no-issue=2
article-no=
start-page=403
end-page=409
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=201401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/PR-negative (n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR > 10 % positive. ESR1 expression was high in 25 % of ER-negative/PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.
en-copyright=
kn-copyright=
en-aut-name=ItohMitsuya
en-aut-sei=Itoh
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=NiikuraNaoki
en-aut-sei=Niikura
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=HayashiNaoki
en-aut-sei=Hayashi
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=HigakiKenji
en-aut-sei=Higaki
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=SymmansW. Fraser
en-aut-sei=Symmans
en-aut-mei=W. Fraser
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=PusztaiLajos
en-aut-sei=Pusztai
en-aut-mei=Lajos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
affil-num=1
en-affil=
kn-affil=Okayama Univ
affil-num=2
en-affil=
kn-affil=Okayama Univ
affil-num=3
en-affil=
kn-affil=Okayama Univ
affil-num=4
en-affil=
kn-affil=Okayama Univ
affil-num=5
en-affil=
kn-affil=Okayama Univ
affil-num=6
en-affil=
kn-affil=Okayama Univ
affil-num=7
en-affil=
kn-affil=Okayama Univ
affil-num=8
en-affil=
kn-affil=Tokai Univ
affil-num=9
en-affil=
kn-affil=St Lukes Int Hosp
affil-num=10
en-affil=
kn-affil=Hiroshima City Hosp
affil-num=11
en-affil=
kn-affil=Hiroshima City Hosp
affil-num=12
en-affil=
kn-affil=Okayama Univ
affil-num=13
en-affil=
kn-affil=Okayama Univ
affil-num=14
en-affil=
kn-affil=Univ Texas MD Anderson Canc Ctr
affil-num=15
en-affil=
kn-affil=Yale Univ
en-keyword=Estrogen receptor
kn-keyword=Estrogen receptor
en-keyword=Progesteron receptor
kn-keyword=Progesteron receptor
en-keyword=cDNA microarray
kn-keyword=cDNA microarray
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Hormone therapy
kn-keyword=Hormone therapy
END
start-ver=1.4
cd-journal=joma
no-vol=28
cd-vols=
no-issue=6
article-no=
start-page=529
end-page=536
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2004
dt-pub=200406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Maintenance of glucose-sensitive insulin secretion of cryopreserved human islets with University of Wisconsin solution and ascorbic acid-2 glucoside
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Normal human islet cells are an ideal source for pancreas-targeted cell therapies, but the availability of human donor pancreata for islet isolation is severely limited. To effectively utilize such scarce donor organs for cell therapies, it is crucial to develop an excellent isolation, effective cryopreservation, and efficient gene transfer techniques for the transportation of isolated cells. In the present study, we investigate the effect of University of Wisconsin (UW) solution and ascorbic acid-2 glucoside (AA2G) on the cryopreservation of human islets. We also evaluate the gene transfer efficiency of a lentiviral vector expressing the E. coli LacZ gene, Lt-NLS/LacZ, in human islets. Human islets were isolated with a standard digestion method at the University of Alberta. Isolated islets were transported to Japan for 40 h and then subjected to cryopreservation experiments. The following preservation solutions were tested: UW solution with 100 mug/mL of AA2G, UW solution, 100% fetal bovine serum (FBS), and CMRL supplemented with 10% FBS. Following three months of cryopreservation, the islets were thawed and analyzed for viability, glucose-sensitive insulin secretion, proinsulin gene expression profile, and in vivo engraftment. The islets were also subjected to monolayer formation with 804G-cell-line-derived extracellular matrix (ECM), followed by Lt-NLS/LacZ transduction. The viability, morphology, glucose-sensitive insulin secretion, proinsulin gene expression, and monolayer formation efficiency of the thawed cryopreserved islets are significantly better maintained by the use of UW solution. When AA2G (100 mug/mL) is combined with UW, such parameters are further improved. The adequate engraftment of UW + AA2G-cryopreserved human islets is achieved in the liver of nude mice. Efficient Lt-NLS/LacZ transduction is identified in monolayered islets cryopreserved with UW solution with AA2G. The present work demonstrates that the combination of UW solution with AA2G (100 mug/mL) would be a useful cryopreservation means for human islets. Human islets monolayer-cultured with 804G-derived ECM are efficiently transduced with a lentiviral vector Lt-NLS/LacZ.
en-copyright=
kn-copyright=
en-aut-name=ArataT
en-aut-sei=Arata
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=OkitsuT
en-aut-sei=Okitsu
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=FukazawaT
en-aut-sei=Fukazawa
en-aut-mei=T
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=IkedaH
en-aut-sei=Ikeda
en-aut-mei=H
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=KobayashiK
en-aut-sei=Kobayashi
en-aut-mei=K
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=YongC
en-aut-sei=Yong
en-aut-mei=C
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=KosakaY
en-aut-sei=Kosaka
en-aut-mei=Y
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=NarushimaM
en-aut-sei=Narushima
en-aut-mei=M
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=MatsuokaJ
en-aut-sei=Matsuoka
en-aut-mei=J
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=YamamotoI
en-aut-sei=Yamamoto
en-aut-mei=I
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=TanakaN
en-aut-sei=Tanaka
en-aut-mei=N
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=LakeyJRT
en-aut-sei=Lakey
en-aut-mei=JRT
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=KobayashiN
en-aut-sei=Kobayashi
en-aut-mei=N
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
affil-num=1
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=2
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=3
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=4
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=5
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=6
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=7
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=8
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=9
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
affil-num=10
en-affil=
kn-affil=Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University
affil-num=11
en-affil=
kn-affil=Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University
affil-num=12
en-affil=
kn-affil=Univ Alberta, Surg Med Res Inst, Clin Islet Transplantat Program
affil-num=13
en-affil=
kn-affil=Department of Surgery, Okayama University Graduate School of Medicine and Dentistry
en-keyword=islets
kn-keyword=islets
en-keyword=University of Wisconsin solution
kn-keyword=University of Wisconsin solution
en-keyword=ascorbic acid-2 glucoside
kn-keyword=ascorbic acid-2 glucoside
en-keyword=cryopreservation
kn-keyword=cryopreservation
en-keyword=stimulation index
kn-keyword=stimulation index
END
start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20131201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Lifestyle factors, including food and nutrition, physical activity, body composition and reproductive factors, and single nucleotide polymorphisms (SNPs) are associated with breast cancer risk, but few studies of these factors have been performed in the Japanese population. Thus, the goals of this study were to validate the association between reported SNPs and breast cancer risk in the Japanese population and to evaluate the effects of SNP genotypes and lifestyle factors on breast cancer risk.
Methods: A case-control study in 472 patients and 464 controls was conducted from December 2010 to November 2011. Lifestyle was examined using a self-administered questionnaire. We analyzed 16 breast cancer-associated SNPs based on previous GWAS or candidate-gene association studies. Age or multivariate-adjusted odds ratios (OR) and 95% confidence intervals (95% CI) were estimated from logistic regression analyses.
Results: High BMI and current or former smoking were significantly associated with an increased breast cancer risk, while intake of meat, mushrooms, yellow and green vegetables, coffee, and green tea, current leisure-time exercise, and education were significantly associated with a decreased risk. Three SNPs were significantly associated with a breast cancer risk in multivariate analysis: rs2046210 (per allele OR = 1.37 [95% CI: 1.11-1.70]), rs3757318 (OR = 1.33[1.05-1.69]), and rs3803662 (OR = 1.28 [1.07-1.55]). In 2046210 risk allele carriers, leisure-time exercise was associated with a significantly decreased risk for breast cancer, whereas current smoking and high BMI were associated with a significantly decreased risk in non-risk allele carriers.
Conclusion: In Japanese women, rs2046210 and 3757318 located near the ESR1 gene are associated with a risk of breast cancer, as in other Asian women. However, our findings suggest that exercise can decrease this risk in allele carriers.
en-copyright=
kn-copyright=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=NishiyamaKeiko
en-aut-sei=Nishiyama
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=IshiharaSetsuko
en-aut-sei=Ishihara
en-aut-mei=Setsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=KawaiHiroshi
en-aut-sei=Kawai
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=KawasakiKensuke
en-aut-sei=Kawasaki
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=IshibeYouichi
en-aut-sei=Ishibe
en-aut-mei=Youichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=OgasawaraYutaka
en-aut-sei=Ogasawara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=KomoikeYoshifumi
en-aut-sei=Komoike
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=MiyoshiShinichiro
en-aut-sei=Miyoshi
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
affil-num=1
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=2
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=3
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=4
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=5
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=6
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=7
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=8
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=9
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=10
en-affil=
kn-affil=Okayama Saiseikai Gen Hosp, Dept Radiol
affil-num=11
en-affil=
kn-affil=Okayama Rousai Hosp, Dept Breast Surg
affil-num=12
en-affil=
kn-affil=Kagawa Prefectural Canc Detect Ctr, Dept Breast Surg
affil-num=13
en-affil=
kn-affil=Mizushima Kyodo Hosp, Dept Breast Surg
affil-num=14
en-affil=
kn-affil=Dept Breast & Endocrinol Surg
affil-num=15
en-affil=
kn-affil=Kinki Univ Hosp, Fac Med
affil-num=16
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
en-keyword=Japanese women
kn-keyword=Japanese women
en-keyword=Asian
kn-keyword=Asian
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Lifestyle
kn-keyword=Lifestyle
en-keyword=Leisure-time exercise
kn-keyword=Leisure-time exercise
en-keyword=Parity
kn-keyword=Parity
en-keyword=Single nucleotide polymorphisms
kn-keyword=Single nucleotide polymorphisms
en-keyword=rs2046210
kn-keyword=rs2046210
en-keyword=rs3757318
kn-keyword=rs3757318
en-keyword=ESR1
kn-keyword=ESR1
END
start-ver=1.4
cd-journal=joma
no-vol=68
cd-vols=
no-issue=6
article-no=
start-page=339
end-page=348
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=201412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Living Will Interest and Preferred End-of-life Care and Death Locations among Japanese Adults 50 and over: A Population-based Survey
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The main purpose of this study was to determine the relationships between Japanese individualsʼ interest in living wills and their preferred end-of-life care and death locations. Questionnaires were mailed to 1,000 individuals aged ァ50 to measure these 2 factors. We examined the associations between the respondentsʼ characteristics and their preferred care and death locations by using multinomial logistic regression models. The response rate was 74%. Home was the most frequently preferred place for end-of-life care (64%), and a palliative care unit (PCU) was the most commonly preferred place to die (51%). Living will interest was associated with a preference for care (odds ratio [OR] 4.74, 95% confidence interval [CI] 1.95-12.1) and death (OR 2.75, 95% CI 1.70-4.47) in a PCU rather than a hospital, but it was not associated with the choice between receiving care or dying at home instead of a hospital. We must consider why Japanese people think home death is impracticable. The Japanese palliative care system should be expanded to meet patientsʼ end-of-life needs, and this includes not only facilitating home care but also increasing access to PCU care.
en-copyright=
kn-copyright=
en-aut-name=NishieHiroyuki
en-aut-sei=Nishie
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=MizobuchiSatoshi
en-aut-sei=Mizobuchi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=SuzukiEtsuji
en-aut-sei=Suzuki
en-aut-mei=Etsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=SatoKenji
en-aut-sei=Sato
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=TodaYuichiro
en-aut-sei=Toda
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=MorimatsuHiroshi
en-aut-sei=Morimatsu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
affil-num=1
en-affil=
kn-affil=Department of Anesthesiology and Resuscitology, Okayama University Hospital
affil-num=2
en-affil=
kn-affil=Department of Anesthesiology and Perioperative Medicine, Kobe University Graduate School of Medicine
affil-num=3
en-affil=
kn-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=4
en-affil=
kn-affil=Department of Anesthesiology and Resuscitology, Okayama University Hospital
affil-num=5
en-affil=
kn-affil=Department of Anesthesiology and Resuscitology, Okayama University Hospital
affil-num=6
en-affil=
kn-affil=Department of Palliative Care Medicine, Okayama University Hospital
affil-num=7
en-affil=
kn-affil=Department of Anesthesiology and Resuscitology, Okayama University Hospital
en-keyword=advance healthcare directive
kn-keyword=advance healthcare directive
en-keyword=living will
kn-keyword=living will
en-keyword=end-of-life care
kn-keyword=end-of-life care
en-keyword=palliative care unit
kn-keyword=palliative care unit
en-keyword=place of death
kn-keyword=place of death
END
start-ver=1.4
cd-journal=joma
no-vol=69
cd-vols=
no-issue=5
article-no=
start-page=291
end-page=299
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=201510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer:NACED-Randomized Multicenter Phase II Trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
en-copyright=
kn-copyright=
en-aut-name=SugiuKumi
en-aut-sei=Sugiu
en-aut-mei=Kumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KellyCatherine M.
en-aut-sei=Kelly
en-aut-mei=Catherine M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=WatanabeNaoki
en-aut-sei=Watanabe
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=ItohMitsuya
en-aut-sei=Itoh
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=HigakiKenji
en-aut-sei=Higaki
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=YuasaTakeshi
en-aut-sei=Yuasa
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=OmoriMasako
en-aut-sei=Omori
en-aut-mei=Masako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=SonobeHiroshi
en-aut-sei=Sonobe
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
affil-num=1
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=2
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=3
en-affil=
kn-affil=Department of Oncology, Mater Misericordiae University Hospital
affil-num=4
en-affil=
kn-affil=Department of Surgery, Chugoku Central Hospital
affil-num=5
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=6
en-affil=
kn-affil=Department of Breast Surgery, Hiroshima City Hospital
affil-num=7
en-affil=
kn-affil=Department of Breast Surgery, Hiroshima City Hospita
affil-num=8
en-affil=
kn-affil=Department of Breast Surgery, Hiroshima City Hospital
affil-num=9
en-affil=
kn-affil=Department of Surgery, Okayama Central Hospital
affil-num=10
en-affil=
kn-affil=Department of Surgery, Himeji Red Cross Hospital
affil-num=11
en-affil=
kn-affil=Department of Pathology, Okayama University Hospital
affil-num=12
en-affil=
kn-affil=Department of Pathology, Chugoku Central Hospital
affil-num=13
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=14
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science b Department of Breast and Endocrine Surgery, Okayama University Hospital
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=neoadjuvant chemotherapy
kn-keyword=neoadjuvant chemotherapy
en-keyword=concurrent hormone therapy
kn-keyword=concurrent hormone therapy
en-keyword=estrogen receptor positive
kn-keyword=estrogen receptor positive
en-keyword=tumor response
kn-keyword=tumor response
END
start-ver=1.4
cd-journal=joma
no-vol=70
cd-vols=
no-issue=5
article-no=
start-page=425
end-page=427
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=201610
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Phase I Trial of 100mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
en-copyright=
kn-copyright=
en-aut-name=TamuraTomoki
en-aut-sei=Tamura
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=HirataTaizo
en-aut-sei=Hirata
en-aut-mei=Taizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=TabataMasahiro
en-aut-sei=Tabata
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=HamadaAkinobu
en-aut-sei=Hamada
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
affil-num=1
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
affil-num=2
en-affil=Department of Medical Oncology, National Hospital Organization Kure Medical Center
kn-affil=
affil-num=3
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Division of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
kn-affil=
affil-num=6
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=7
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=9
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=10
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=11
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=12
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=13
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=phase I trial
kn-keyword=phase I trial
en-keyword=docetaxel
kn-keyword=docetaxel
END
start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=2
article-no=
start-page=288
end-page=298
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2017
dt-pub=201703
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=BACKGROUND:
An understanding of health-related quality of life (HRQOL) is of utmost importance in both oncological and esthetic breast surgery. The BREAST-Q is a patient-reported outcome (PRO) measure that investigates HRQOL and patient satisfaction before and after breast surgery. The aim of this study was to develop a Japanese version of the BREAST-Q including the mastectomy module, the reconstruction module, the augmentation module and the reduction/mastopexy module, and to assess the psychometric properties of the mastectomy module among Japanese women.
METHODS:
The Japanese version of the BREAST-Q was developed through forward translation, backward translation and patient testing. Traditional psychometric testing of the mastectomy module was administered to 45 post-mastectomy patients.
RESULTS:
The mastectomy, reconstruction, augmentation and reduction/mastopexy modules were formally developed into Japanese. Despite cultural difference between Japanese women and original target population, the contents were considered to be valid among Japanese woman. With the exception of the sexual well-being subscale, good reliability and validity were evident for the mastectomy module (Test-retest reliability 0.76-0.95, Chronbach's alpha coefficient 0.77-0.98).
CONCLUSIONS:
The BREAST-Q Japanese version is a useful PRO measure for investigating the impact of breast surgery on HRQOL and patient satisfaction. Further validation in younger Japanese women is needed to determine the usefulness of the sexual well-being subscale.
en-copyright=
kn-copyright=
en-aut-name=SaigaMiho
en-aut-sei=Saiga
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KimataYoshihiro
en-aut-sei=Kimata
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=WatanabeSatoko
en-aut-sei=Watanabe
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MukaiYuko
en-aut-sei=Mukai
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=ShimozumaKojiro
en-aut-sei=Shimozuma
en-aut-mei=Kojiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
affil-num=1
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=
affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=
kn-affil=
affil-num=4
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University
kn-affil=
affil-num=7
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=9
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=10
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=11
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=12
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=13
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=BREAST-Q
kn-keyword=BREAST-Q
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Breast reconstruction
kn-keyword=Breast reconstruction
en-keyword=Health-related quality of life
kn-keyword=Health-related quality of life
en-keyword=Satisfaction
kn-keyword=Satisfaction
END
start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=2
article-no=
start-page=117
end-page=124
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=202004
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction
Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy.
Patients and Methods
We retrieved publicly available complementary DNA microarray data from 399 human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer samples from patients who underwent standard neoadjuvant chemotherapy. We analyzed the messenger RNA (mRNA) expression levels of key breast cancer markers and therapeutic target genes according to residual cancer burden (RCB) classification: RCB-0/I, RCB-II, and RCB-III.
Results
Among hormone receptor–positive samples, there were more luminal A tumors by PAM50 (Prediction Analysis of Microarray 50 [Prosigna], aka Prosigna Breast Cancer Prognostic Gene Signature Assay) in RCB-III than in RCB-0/I and RCB-II (P < .01). The mRNA expressions of ESR1 and PGR were significantly higher, and that of MKI67 was lower in RCB-II and RCB-III than in RCB-0/I. The mRNA expression of cyclin D1 was up-regulated in RCB-III and that of CDKN2A was down-regulated in RCB-III (P = .027 and < .01). Among triple-negative (TN) samples, RCB-III had higher clinical stage and more lymph node–positive samples than RCB-0/1 and RCB-II (P < .01). In both subtypes, VEGF-C expression was significantly higher in RCB-III than in RCB-0/I and RCB-II.
Conclusion
In hormone receptor–positive breast cancer, biological features such as luminal A were associated with RCB; this trend was not observed in TN breast cancer. Further, some targeted therapies should be tested as new strategies after standard neoadjuvant chemotherapy in future clinical trials.
en-copyright=
kn-copyright=
en-aut-name=TakahashiYuko
en-aut-sei=Takahashi
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=SuzukiYoko
en-aut-sei=Suzuki
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=HatonoMinami
en-aut-sei=Hatono
en-aut-mei=Minami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=TsukiokiTakahiro
en-aut-sei=Tsukioki
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=KawadaKengo
en-aut-sei=Kawada
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=KochiMariko
en-aut-sei=Kochi
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=IkedaHirokuni
en-aut-sei=Ikeda
en-aut-mei=Hirokuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=6
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=8
en-affil=Departments of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=9
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=10
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=11
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=12
en-affil=Departments of Palliative and Supportive Medicine, Okayama University Hospital
kn-affil=
affil-num=13
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=14
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Gene expression
kn-keyword=Gene expression
en-keyword=Hormone receptor positive
kn-keyword=Hormone receptor positive
en-keyword=Residual tumor burden
kn-keyword=Residual tumor burden
en-keyword=Targeted therapy
kn-keyword=Targeted therapy
en-keyword=Triple negative
kn-keyword=Triple negative
END
start-ver=1.4
cd-journal=joma
no-vol=29
cd-vols=
no-issue=
article-no=
start-page=1287
end-page=1297
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200704
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Demand for weekend outpatient chemotherapy among patients with cancer in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background
Advanced cancer therapeutics have improved patient survival, leading to an increase in the number of patients who require long-term outpatient chemotherapy. However, the available schedule options for chemotherapy are generally limited to traditional business hours.
Method
In 2017, we surveyed 721 patients with cancer in Okayama, Japan, regarding their preferences for evening and weekend (Friday evening, Saturday, and Sunday) chemotherapy appointments.
Results
A preference for evening and weekend appointment options was indicated by 37% of the respondents. Patients who requested weekend chemotherapy were younger, female, with no spouse or partner, living alone, employed, and currently receiving treatment. Among these factors, age and employment status were significantly associated with a preference for weekend chemotherapy, according to multivariate analysis.
Conclusion
Our findings reveal a demand for evening and weekend outpatient chemotherapy, especially among young, employed patients.
en-copyright=
kn-copyright=
en-aut-name=KatayamaHideki
en-aut-sei=Katayama
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TabataMasahiro
en-aut-sei=Tabata
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
affil-num=1
en-affil=Department of Palliative and Supportive Care, Okayama University Hospital
kn-affil=
affil-num=2
en-affil=Department of Palliative and Supportive Care, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Palliative and Supportive Care, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Palliative and Supportive Care, Okayama University Hospital
kn-affil=
en-keyword=Weekend chemotherapy
kn-keyword=Weekend chemotherapy
en-keyword=Outpatient
kn-keyword=Outpatient
en-keyword=Social burden
kn-keyword=Social burden
en-keyword=Cancer patient
kn-keyword=Cancer patient
END
start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=4
article-no=
start-page=431
end-page=437
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2021
dt-pub=202108
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to evaluate whether there are differences in the attitudes and practices of cancer pain manage-ment between medical oncologists and palliative care physicians. An online nationwide survey was used to collect responses from board-certified medical oncologists and palliative care physicians in Japan. The survey questionnaire comprised 30 questions. The differences in responses between medical oncologists and palliative care physicians were examined. Out of the 1,227 questionnaires sent, 522 (42.5%) were returned. After apply-ing the exclusion criteria, 445 questionnaires (medical oncologists: n = 283; palliative care physicians: n = 162) were retained for analysis. Among the questions about potential barriers to optimal cancer pain man-agement, both medical oncologists and palliative care physicians considered the reluctance of patients to take opioids due to fear of adverse effects as the greatest barrier. Significantly different ratings between medical oncologists and palliative care physicians were observed on 5 of the 8 questions in this area. Significantly differ-ent ratings were observed for all questions concerning pain specialists and their knowledge. For effective cancer pain management, it is important to account for differences in attitudes and practice between medical oncolo-gists and palliative care physicians.
en-copyright=
kn-copyright=
en-aut-name=KunitomiToshiki
en-aut-sei=Kunitomi
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=NasuJunichirou
en-aut-sei=Nasu
en-aut-mei=Junichirou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=MinamiDaisuke
en-aut-sei=Minami
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=NishieHiroyuki
en-aut-sei=Nishie
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=SaitoShinya
en-aut-sei=Saito
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=2
en-affil=Department of Internal Medicine, Okayama Saiseikai General Hospital
kn-affil=
affil-num=3
en-affil=Palliative Care Team, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=5
en-affil=Palliative Care Team, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Palliative Care Team, Okayama University Hospital
kn-affil=
affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=cancer pain management
kn-keyword=cancer pain management
en-keyword=opioid
kn-keyword=opioid
en-keyword=medical oncologist
kn-keyword=medical oncologist
en-keyword=palliative care physician
kn-keyword=palliative care physician
en-keyword=barriers
kn-keyword=barriers
END